Resolutions for the General Meeting of Shareholders
ExtraordinaryPartial Amendment to the Articles of Incorporation
Shareholder ProposalMatter concerning the dismissal of Director Watanabe Shuichi (渡辺秀一)
Matter concerning the distribution of surplus (special dividend)
Acquisition of treasury shares
A shareholder proposal has been submitted by a proposing shareholder. Proposal No. 1 is both a company proposal and a shareholder proposal, while Proposals No. 2 through No. 4 are shareholder proposals. The Board of Directors opposes Proposals No. 2 through No. 4.
A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.| Item | Details |
|---|---|
| Type of shareholders' meeting | Extraordinary |
| Date and time | 10:00 a.m., 15 December 2026 (Tuesday) |
| Matters for resolution | Proposal No. 1: Partial Amendment to the Articles of Incorporation, Proposal No. 2: Matter concerning the dismissal of Director Watanabe Shuichi (渡辺秀一), Proposal No. 3: Matter concerning the distribution of surplus (special dividend), Proposal 4: Acquisition of treasury shares |
| Shareholder Proposal | A shareholder proposal has been submitted by a proposing shareholder. Proposal No. 1 is both a company proposal and a shareholder proposal, while Proposals No. 2 through No. 4 are shareholder proposals. The Board of Directors opposes Proposals No. 2 through No. 4. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.An extraordinary general meeting of shareholders will be held at the request of shareholders. The Board of Directors opposes Proposal No. 2 on the grounds that a smooth transition to the new management structure and the experience and knowledge of Watanabe Shuichi (渡辺秀一) are necessary, Proposal No. 3 on the grounds that securing growth investment opportunities must be balanced with stable shareholder returns, and Proposal No. 4 on the grounds of maintaining financial soundness and a stable supply of pharmaceuticals and other products.